Figure 2个  Table 1
    • SourceAntibodiesCross reactivityBlocking receptor bindingTargetComplex crystal (PDB ID) Binding affinity (Kd nmol/L) Neutralizing effect (IC50 μg/mL or nmol/L) Current statusRefs.
      Convalescent SARS patients 47D11 Yes No RBD NA 9.6b 0.57 μg/mL Under research Wang C et al. (2020)
      S309 Yes No RBD (Site B) 6WPS 0.001b 0.079 μg/mL Under research Pinto et al. (2020)
      CR3022 Yes No RBD (Site C) 6W41 < 0.1b No Under research Yuan et al. (2020b)
      Immunized llama VHH-72-Fc Yes Yes RBD NA 38.6a 0.2* μg/mL Under research Wrapp et al. (2020a)
      Convalescent COVID-19 patients P2C-1F11 No Yes RBD (Site A) NA 2.12a 0.03 μg/mL Under research Ju et al. (2020)
      P2B-2F6 No Yes RBD (Site A) 7BWJ 5.14a 0.41 μg/mL Under research
      CA1 No Yes RBD (Site A) NA 4.68 ± 1.64a 4.981 μg/mL Under research Shi et al. (2020)
      CB6 (JS016) No Yes RBD (Site A) 7C01 2.49 ± 1.65a 0.835 μg/mL Phase-I
      B38 No Yes RBD (Site A) 7BZ5 70.1a 0.177 μg/mL Under research Wu Y et al. (2020)
      H4 No Yes RBD (Site A) NA 4.48a 0.896 μg/mL Under research
      414-1 No Yes RBD (Site A) NA 0.31c 1.75 nmol/L Under research Wan et al. (2020)
      505-3 No Yes RBD (Site A) NA 0.08c 3 nmol/L Under research
      BD-23 NA Yes RBD (Site A) 7BYR 4.3a 8.5 μg/mL Under research Cao et al. (2020)
      BD-368-2 NA Yes RBD (Site A) NA 0.82a 0.015 μg/mL Under research
      CC6.29 No Yes RBD (Site A) NA 1.20a 0.002* μg/mL Under research Rogers et al. (2020)
      CC6.30 No Yes RBD (Site A) NA 1.71a 0.001* μg/mL Under research
      CC12.1 No Yes RBD (Site A) 6XC2 5.92a 0.022* μg/mL Under research Yuan et al. (2020a)
      CC12.3 No Yes RBD (Site A) 6XC4 54.3a 0.026* μg/mL Under research
      4A8 NA No NTD (Site D) 7C2L 1.00b 0.39 μg/mL Under research Chi et al. (2020)
      2–4 NA Yes RBD (Site A) 6XEY NA 0.057 μg/mL Under research Liu LH et al. (2020)
      2–15 NA Yes RBD NA NA 0.0007 μg/mL Under research
      4–8 NA No NTD NA NA 0.009 μg/mL Under research
      2–43 NA Yes RBD NA NA 0.003 μg/mL Under research
      COV2-2196 No Yes RBD NA NA 0.015 μg/mL Under research Zost et al. (2020)
      COV2-2130 No Yes RBD NA NA 0.107 μg/mL Under research
      S2M11 No Yes RBD (Site A) 7K43 66a 1.66 μg/mL Under research Poh et al. (2020)
      S2E12 No Yes RBD (Site A) 7K4N 1.6a 5.29 μg/mL Under research
      LY-CoV555 No Yes RBD NA NA NA Phase III (pause) Jones et al. (2020)
      REGN10933 No Yes RBD 6XDG 0.0140a 0.043 nmol/L Phase III Baum et al. (2020)
      VelocImmune mice REGN10987 No Yes RBD 6XDG 0.0298a 0.041 nmol/L Phase III
      Phage library n3088 NA No RBD (Site C) NA 12.6b 3.3* μg/mL Under research Wu YL et al. (2020)
      n3130 NA No RBD (Site C) NA 32.5b 3.7* μg/mL Under research
      n3086 NA No RBD NA 88.97b 26.6* μg/mL Under research
      n3113 NA No RBD NA 57.01b 18.9* μg/mL Under research
      H014 Yes Yes RBD (Site C) NA 0.33b 1* nmol/L Under research Lv et al. (2020)
      The data were derived from authentic virus neutralization experiments
      * The data were derived from the pseudovirus neutralization experiments
      aThe data obtained using surface plasmon resonance (SPR)
      bThe data obtained using biolayer interferometry (BLI)
      cThe data obtained using enzyme-linked immunosorbent assay (ELISA)
      *The data were derived from the pseudovirus neutralization experiment (other data derived from authentic virus neutralization experiments)

      Table 1.  Characteristics of representative antibodies to SARS-CoV-2.